Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin

European Journal of Internal Medicine

Volumn 19, Issue 4, 2008, Pages 266-270

  Elefsiniotis, Ioannis S ^a   Pavlidis, Christos ^b   Ketikoglou, Ioannis ^a   Koutsounas, Sotirios ^b   Scarmeas, Nikolaos ^c   Pantazis, Konstantinos D ^a   Moulakakis, Antonios ^a   Tsianos, Epameinondas V ^d  

^a HIPPOKRATION HOSPITAL   (Greece)

^b National Centre for Viral Hepatitis   (Greece)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d Medical School   (Greece)

Author keywords

Age; Genotype; Hepatitis C; High viral load; Liver histology

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; GENOTYPE; GREECE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; BIOPSY, NEEDLE; FEMALE; FORECASTING; GENOTYPE; GREECE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 43049155970     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.06.014     Document Type: Article

References (19)

1. Mc Hutchinson J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
2. Lai M.Y., Kao J.H., Yang P.M., Wang J.T., Chen P.J., Chan K.W., et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 111 (1996) 1307-1312
3. NIH Consensus Statement on Management of Hepatitis. NIH Consens. State Science Statements 19 3 (2002) 1-46 June 10-12, 2002
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon a-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 140 (2004) 346-355
5. Manns M.P., Mc Hutchinson J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales Jr. F.L., et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
7. Heathcote E.J., Shiffman M.L., Cooksley G.E., Dusheiko G.M., Lee S.S., Balart L., et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343 (2000) 1673-1680
8. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
9. Monto A., Alonzo J., Watson J.J., Grunfeld C., and Wright T.L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology 36 (2002) 729-736
10. Gasteyger C., and Tremblay A. Metabolic impact of body fat distribution. J Endocrinol Invest 25 (2002) 876-883
11. Sanyal A.J., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Stravitz R.T., et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98 (2003) 2064-2071
12. Tarantino G., Conca P., Sorrentino P., and Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 21 (2006) 1266-1268
13. Mc Hutchinson J.G., Manns M.P., Patel K., Poynard T., Lindsay K.L., Trepo C., et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 123 (2002) 1061-1069
14. Davis G.L., Wong J.B., Mc Hutchinson J.G., Manns M.P., Harvey J., and Albrecht J. Early virological response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
15. Manns M.P. Adhérence to combination therapy: influence on sustained virological response and economic impact. Gastroenterol Clin North Am 33 1 suppl. (2004) s11-s24
16. Derbala M., Amer A., Bener A., Lopez A.C., Omar M., and El Ghannam M. Pegylated interferon alpha2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 12 (2005) 380-385
17. Hasan F., Asker B., AI-Khaldi J., Siddique I., Al-Ajmi M., Owaid S., et al. Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 99 (2004) 1733-1737
18. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
19. Alessi N., Freni M.A., Spadaro A., Ajello A., Turiano S., Migliorato D., et al. Efficacy of interferon treatment in elderly patients with chronic hepatitis C. Infez Med 11 (2003) 208-212